Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned a consensus rating of “Hold” from the nine brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $3.00.

Several equities research analysts have recently commented on RGLS shares. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research report on Wednesday, July 12th. Chardan Capital cut shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research note on Monday, June 12th. ValuEngine lowered shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd.

In other news, insider Joseph P. Hagan acquired 219,780 shares of Regulus Therapeutics stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, with a total value of $199,999.80. Following the purchase, the insider now directly owns 241,297 shares of the company’s stock, valued at $219,580.27. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Daniel R. Chevallard acquired 54,945 shares of Regulus Therapeutics stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the purchase, the chief financial officer now directly owns 59,415 shares in the company, valued at $54,067.65. The disclosure for this purchase can be found here. Insiders have purchased a total of 549,450 shares of company stock worth $500,000 in the last three months. 4.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC raised its position in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the last quarter. Wedbush Securities Inc. raised its position in shares of Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 93,420 shares during the last quarter. South Dakota Investment Council raised its position in shares of Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its position in shares of Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the last quarter. 21.93% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics (NASDAQ RGLS) traded up 1.00% during mid-day trading on Friday, reaching $1.01. 383,373 shares of the company traded hands. The stock’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.23. Regulus Therapeutics has a one year low of $0.79 and a one year high of $3.65. The firm’s market cap is $104.82 million.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Analysts forecast that Regulus Therapeutics will post ($1.02) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Regulus Therapeutics Inc. (RGLS) Receives Consensus Rating of “Hold” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/02/regulus-therapeutics-inc-rgls-receives-consensus-rating-of-hold-from-analysts.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.